Quince Therapeutics, Inc. (NASDAQ:IRLA) Shares Shorted: Short Interest Up 158.1% in October

Quince Therapeutics, Inc. (NASDAQ:IRLA) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 154,736 shares, an increase of 158.1% from the September 30th total of 59,944 shares. Approximately 16.1% of the shares of the company are short sold. Based on an average daily volume of 46,846 shares, the short-interest ratio is presently 3.3 days.

Quince Therapeutics Stock Down 4.1%

Shares of Quince Therapeutics stock traded down $1.34 during trading hours on Thursday, reaching $31.62. 64,261 shares of the company’s stock were exchanged, compared to its average volume of 80,308. Quince Therapeutics has a 1 year low of $15.10 and a 1 year high of $909.98.

Analyst Ratings Changes

A number of research analysts have recently weighed in on IRLA shares. Raymond James Financial raised Quince Therapeutics to a “moderate buy” rating in a report on Friday, October 9th. Weiss Ratings started coverage on Quince Therapeutics in a research report on Tuesday, October 13th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Quince Therapeutics Company Profile

Quince Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s primary program is EryDex, an investigational therapy designed to deliver dexamethasone through a patient’s own red blood cells.

EryDex is being evaluated for the treatment of ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological impairment, immune-system problems and other serious complications.